The Need for Point-of-Care HbA1c Testing for Diabetes
Continuously improving POC technologies offer benefits for patients, practices, and payors.
Read MorePosted by Melissa Mayer | Sep 10, 2018 | Cerebrovascular, Disease States, Stroke |
Continuously improving POC technologies offer benefits for patients, practices, and payors.
Read MorePosted by Melissa Mayer | Sep 8, 2018 | Cerebrovascular, Diagnostic Technologies, Stroke |
Glycated serum protein, lipoprotein (a), and cystatin c Microtip Partnership assays are now available for use on the Vitros 4600 clinical chemistry system and the Vitros 5600 integrated chemistry and immunoassay system.
Read MorePosted by Steve Halasey | Sep 7, 2018 | Clinical Chemistry Analyzers, Culture Media, POC Reagents & Test Kits |
Glycated albumin provides a sensitive intermediate-term marker for glycemic control in diabetes.
Read MorePosted by Melissa Mayer | Aug 31, 2018 | Disease States |
This is a companion article to “The Need for Point-of-Care HbA1c Testing for Diabetes.”
Read MorePosted by Melissa Mayer | Aug 30, 2018 | Disease States |
This is a companion article to “The Need for Point-of-Care HbA1c Testing for Diabetes.”
Read More